Research programme: viral vaccines - Innogenetics

Drug Profile

Research programme: viral vaccines - Innogenetics

Alternative Names: ED 002; ED 009; EP 2220; EP 2230; GNI-103; GNI-105

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genencor International; Pharmexa-Epimmune
  • Developer Innogenetics; Pharmexa-Epimmune
  • Class Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C; Human papillomavirus infections

Most Recent Events

  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
  • 09 Sep 2008 Innogenetics has been acquired by Solvay Pharmaceuticals
  • 05 Sep 2007 Preclinical development of vaccine candidates ED 002 and ED 009 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top